Mergers & Acquisitions Mergers & Acquisitions

Deals like Amgen-Horizon won’t necessarily bring US FTC settlement, agency official says

US pharmaceutical deals that are comparable to the Amgen-Horizon transaction, which was resolved via a mid-litigation consent decree with a behavioral remedy, may not be addressed by the Federal Trade Commission in precisely the same way, an FTC official said today.
“These are very, very fact-specific analyses, and so,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News